Daiwa Sangyo Co., Ltd. (大和産業株式会社) is a Japanese pharmaceutical intermediate and contract manufacturing organization (CMO) headquartered in Tokyo, with manufacturing facilities in the Osaka region. Founded in 1975, the company has evolved from a regional chemical supplier to a critical partner in Japan's pharmaceutical supply chain, specializing in high-potency intermediates and custom synthesis for central nervous system (CNS) drugs[1].
Unlike companies focused on finished drug products, Daiwa Sangyo operates as a B2B supplier providing pharmaceutical intermediates and active pharmaceutical ingredient (API) building blocks to major Japanese pharmaceutical companies including Takeda Pharmaceutical, Eisai, Astellas Pharma, and Mitsubishi Tanabe Pharma. This position in the supply chain places them at the foundation of Japan's neurodegeneration drug development ecosystem.
Daiwa Sangyo operates GMP-certified manufacturing facilities in Japan, serving as a critical supply chain node for CNS drug development across Japan[2]. Their capabilities span:
The company provides custom synthesis services for pharmaceutical companies developing new CNS drugs, including:
Alzheimer's disease drug intermediates: Building blocks for amyloid-beta targeting compounds, BACE inhibitors, and anti-tau therapies. Daiwa Sangyo has supplied key intermediates for programs developed by Eisai and Takeda[3].
Parkinson's disease therapies: Intermediates for dopamine agonists (pramipexole, ropinirole analogues), MAO-B inhibitors (selegiline, rasagiline), and COMT inhibitors[4].
Novel CNS drug delivery systems: Partnerships for nanoparticle and liposomal formulation components targeting the blood-brain barrier.
| Capability | Scale | Application |
|---|---|---|
| Custom synthesis | Gram to metric tons | Early to late-stage clinical |
| Process development | Lab to pilot scale | Process optimization and validation |
| Scale-up | Pilot to commercial scale | Manufacturing transfer and tech transfer |
| Regulatory support | Pre-IND to NDA | Japanese PMDA, US FDA, EU EMA submissions |
Daiwa Sangyo's role in neurodegeneration research extends beyond simple supply:
The company has established long-term supply agreements with major Japanese pharmaceutical companies that are active in neurodegeneration drug development. Through AMED-funded research programs, Daiwa Sangyo supports the development of novel CNS drugs by providing critical intermediates that would otherwise require importation or complex synthesis routes[5].
Daiwa Sangyo maintains comprehensive quality certifications supporting global pharmaceutical regulatory requirements:
| System | Certification | Scope |
|---|---|---|
| GMP (Japan) | PMDA compliance | Manufacturing of pharmaceutical intermediates |
| GMP (US) | FDA 21 CFR 210/211 | API and intermediate manufacturing |
| GMP (EU) | EMA ICH Q7 | European market supply |
| ISO 9001 | JIS Q 9001 | Quality management systems |
| ISO 14001 | JIS Q 14001 | Environmental management |
The company's quality control laboratories perform comprehensive testing including high-performance liquid chromatography (HPLC), gas chromatography (GC), mass spectrometry (MS), nuclear magnetic resonance (NMR), and impurity profiling to meet pharmaceutical regulatory standards across Japan, the US, and Europe.
Daiwa Sangyo operates on a B2B model serving:
The company's strategic focus on high-potency and controlled substances provides differentiation from commodity chemical suppliers, as these materials require specialized handling, dedicated facilities, and strict regulatory compliance.
Daiwa Sangyo Co., Ltd. Corporate Website - Pharmaceutical Intermediates and Custom Synthesis. 2024. ↩︎
Pharmaceutical and Medical Devices Agency (Japan). Guide to Drug Approval in Japan - GMP Standards for Intermediates. 2024. ↩︎
Takeda Pharmaceutical Company. Contract manufacturing partnerships in Japanese pharma supply chain. Pharmaceutical Medicine. 2023. ↩︎
Tanaka K, Yamamoto H. Pharmaceutical intermediate manufacturing trends in Japan: CNS drug development perspective. Yakugaku Zasshi. 2023. ↩︎
Japan Agency for Medical Research and Development. AMED CNS Drug Development Support Programs 2024. 2024. ↩︎